Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Japanese Patients With Generalized Pustular Psoriasis
NCT01952015Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in generalized pustular psoriasis (GPP), sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT01952015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952015.